Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. The Rockwell Medical (RMTI) news feed on Stock Titan focuses on company announcements that relate to its hemodialysis concentrates portfolio, supply agreements with dialysis providers, operational updates, and financial results.
Investors and healthcare observers following RMTI news can expect coverage of product purchase agreements with large dialysis providers, health systems, and specialized care organizations. Recent company communications describe multi-year contracts that include utilization or purchase minimums, options to renew, and supply of liquid and dry acid and bicarbonate concentrates, as well as Rockwell Medical’s dry acid concentrate mix system and bicarbonate cartridge. News items also highlight the company’s efforts to expand its customer base, including adding new dialysis customers in different regions of the United States.
The RMTI news stream also includes quarterly financial and operational results, typically released through earnings press releases and accompanied by conference call details. These updates discuss net sales, gross margin, adjusted EBITDA, and cash position, along with commentary on customer transitions, contract renewals, and manufacturing efficiency. In addition, Rockwell Medical issues news on leadership changes, such as board appointments and executive promotions, and on operational roles related to manufacturing and supply chain management.
Further topics in Rockwell Medical news include participation in industry events, such as exhibiting its hemodialysis concentrates portfolio at professional nephrology conferences, and recognition as a Great Place to Work® and a Fortune Best Workplaces in Manufacturing & Production™ honoree. For users tracking RMTI, this news page provides a centralized view of the company’s corporate developments, financial disclosures, and updates on its hemodialysis products and customer relationships.
Rockwell Medical (RMTI) announced the appointment of Russell L. Skibsted as Executive Vice President, Chief Financial Officer, and Chief Business Officer effective September 15, 2020. Skibsted's extensive experience in the life sciences sector, including previous roles at AgeX and BioTime, aligns with the company's focus on enhancing its commercial strategy for Triferic and Triferic AVNU in kidney dialysis. He aims to drive business development and financial operations, ultimately increasing shareholder value.
Rockwell Medical (Nasdaq: RMTI) has announced an exclusive license agreement with Jeil Pharmaceutical Co., Ltd. for the commercialization of Triferic in South Korea. Under this agreement, Jeil will develop and market Triferic, with Rockwell supplying the product. The deal includes an upfront fee, milestone payments, and royalties on sales. Triferic aims to address iron deficiency in over 78,000 hemodialysis patients in South Korea. Sales are expected to commence in early 2022, pending regulatory approval.
Rockwell Medical (Nasdaq: RMTI) will host a conference call and webcast on September 24, 2020, at 4:30 p.m. ET, to discuss novel applications of ferric pyrophosphate citrate (FPC) for treating iron deficiency in home infusion therapy and acute heart failure patients. Key opinion leaders will join the call alongside company representatives. The goal is to explore new indications for FPC technology beyond hemodialysis. Access details are provided for interested stakeholders.
Rockwell Medical announced that its executive management team will present at two important investor conferences in September 2020. The first is the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 4:00 PM EDT, followed by the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15 at 10:40 AM EDT. Both presentations will be available via live webcast on the company's website for 30 days.
Rockwell Medical focuses on transforming anemia management, particularly for end-stage kidney disease patients, with FDA-approved therapies like Triferic Dialysate and Triferic AVNU.
Rockwell Medical has appointed Dr. Allen R. Nissenson to its Board of Directors effective June 11, 2020. An expert in kidney disease and former Chief Medical Officer of DaVita Kidney Care, Dr. Nissenson's extensive experience is expected to bolster the company's mission of enhancing anemia management in end-stage renal disease (ESRD) patients. This strategic move aims to strengthen Rockwell's leadership as it seeks to expand the reach of its FDA-approved products, Triferic Dialysate and Triferic AVNU, both crucial for iron replacement in hemodialysis patients.
Rockwell Medical (Nasdaq: RMTI) announced the submission of a New Drug Submission (NDS) to Health Canada for Triferic AVNU, an iron replacement therapy for adult hemodialysis patients with chronic kidney disease. This marks the Company's first international regulatory filing for this intravenous drug. If approved, Triferic AVNU is expected to become a vital treatment option in Canada, benefiting over 20,000 patients. Rockwell Medical has a distribution agreement with RMC Canada, contingent on regulatory approval.